Molecular target
RANKL (Receptor Activator of NF-κB Ligand)
Cytokine signaling osteoclast differentiation and bone resorption. Antagonism (denosumab) reduces bone resorption — alternative mechanism to bisphosphonates for osteoporosis and bone-metastasis-related skeletal events.
Educational use only. This page summarizes published research and traditional-use records for educational purposes. It does not diagnose, treat, cure, or prevent any disease. Do not start, stop, or change medications based on this information. Discuss any decisions about therapies — pharmaceutical or botanical — with a qualified clinician who knows your medical history.
No PHI / HIPAA notice: Do not share Protected Health Information (PHI) of any patient on this site — including names, dates of birth, addresses, MRNs, or any identifying information. Use abstract case framing only. Sharing PHI with non-covered entities risks HIPAA violation regardless of platform capability.
Pharmaceutical agents
Drugs that act on RANKL (Receptor Activator of NF-κB Ligand)
These medications have RANKL (Receptor Activator of NF-κB Ligand) among their molecular targets. Sharing a target is a mechanistic relationship — it does not make any plant below an alternative to, or substitute for, these drugs.
Botanical connections
Plants whose compounds act on RANKL (Receptor Activator of NF-κB Ligand)
Each plant below contains a named compound documented to act on RANKL (Receptor Activator of NF-κB Ligand). The compound and the reason for the connection are shown on every edge — a shared mechanism, not a therapeutic equivalence.
- Iridoids (aucubin, geniposidic acid)Iridoid glycosides
He et al. 2014 review cites preclinical evidence linking iridoid constituents to bone-protective effects, potentially involving RANKL signaling.